Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

NHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy from April 2019. The new decision means that Afinitor will be ...

The approval is for the Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) of ...

Natco Pharma has received US FDA approval for its generic version of Everolimus tablets for oral suspension, indicated for ...

Vandana Singh Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases An Alphabet-backed startup is poised to ...

NATCO Pharma said that it has received approval of its ANDA for Everolimus tablets for oral suspension (TFOS), a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation.

Natco Pharma announced approval of its ANDA for Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation. NATCO's ...